Interim Data for Merck’s MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Previously Treated Patients with Non-Small Cell Lung Cancer to be Presented at 15th World Conference on Lung Cancer
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
confirmed today that interim data from the company’s Phase IB expansion
study (PN 001) evaluating the efficacy and safety of *MK-3475 in
patients with refractory non-small cell lung cancer (NSCLC) is scheduled
for presentation at the 15th
World Conference on Lung Cancer on Oct. 29 at 4:15 p.m., (1:15 a.m.
EDT), in Sydney, Australia.
Language:
English
Contact:
MerckMedia:Caroline Lappetito, 267-305-7639Claire Mulhearn, 908-423-7425orInvestor:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news
More News: Cancer | Cancer & Oncology | Conferences | Lung Cancer | Merck | Non-Small Cell Lung Cancer | Pharmaceuticals | Study